Tucson, AZ – According to filings with the U.S. Securities and Exchange Commission, Accelerate Diagnostics is raising $32,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Steve Reichling played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

To learn more about Accelerate Diagnostics, visit http://acceleratediagnostics.com/

Contact:
Steve Reichling, Chief Financial Officer
520-365-3100
https://www.linkedin.com/in/steve-reichling-7859991/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved